Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6525) 6525
Book Review (1330) 1330
Publication (272) 272
Book Chapter (22) 22
Conference Proceeding (22) 22
Magazine Article (9) 9
Newsletter (8) 8
Dissertation (3) 3
Web Resource (3) 3
Book / eBook (2) 2
Paper (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5748) 5748
humans (5596) 5596
octreotide - therapeutic use (3818) 3818
male (3283) 3283
female (3012) 3012
octreotide (2696) 2696
middle aged (2415) 2415
adult (2081) 2081
aged (1632) 1632
somatostatin - analogs & derivatives (1278) 1278
endocrinology & metabolism (1169) 1169
somatostatin (1168) 1168
somatostatin - therapeutic use (1086) 1086
treatment outcome (1085) 1085
animals (880) 880
oncology (860) 860
abridged index medicus (836) 836
octreotide - administration & dosage (801) 801
acromegaly - drug therapy (792) 792
antineoplastic agents, hormonal - therapeutic use (778) 778
octreotide - analogs & derivatives (731) 731
surgery (697) 697
gastroenterology & hepatology (686) 686
tumors (634) 634
medicine & public health (624) 624
gastrointestinal agents - therapeutic use (619) 619
management (601) 601
therapy (590) 590
octreotide - adverse effects (548) 548
acromegaly (526) 526
neuroendocrine tumors (476) 476
octreotide - pharmacology (454) 454
cancer (447) 447
pharmacology & pharmacy (440) 440
aged, 80 and over (420) 420
rats (410) 410
antineoplastic agents - therapeutic use (408) 408
medicine, general & internal (408) 408
receptors, somatostatin - metabolism (387) 387
care and treatment (383) 383
retrospective studies (363) 363
time factors (360) 360
pancreatic neoplasms - drug therapy (348) 348
pituitary neoplasms - drug therapy (344) 344
diagnosis (341) 341
somatostatin analog (327) 327
prospective studies (326) 326
adolescent (325) 325
radionuclide imaging (318) 318
somatostatin analogs (317) 317
peptides, cyclic - therapeutic use (315) 315
radiology, nuclear medicine & medical imaging (311) 311
radiopharmaceuticals - therapeutic use (311) 311
combined modality therapy (307) 307
health aspects (299) 299
neuroendocrine tumors - drug therapy (299) 299
adenoma - drug therapy (286) 286
expression (282) 282
tomography, x-ray computed (281) 281
hormones - therapeutic use (278) 278
growth-hormone (274) 274
insulin-like growth factor i - metabolism (274) 274
follow-up studies (267) 267
sms 201-995 (265) 265
mice (263) 263
neuroendocrine tumors - radiotherapy (258) 258
acromegaly - blood (257) 257
antineoplastic combined chemotherapy protocols - therapeutic use (249) 249
growth hormone - blood (249) 249
liver neoplasms - secondary (249) 249
lanreotide (246) 246
chemotherapy (245) 245
efficacy (244) 244
octreotide - pharmacokinetics (240) 240
analysis (234) 234
prognosis (232) 232
drug therapy (225) 225
magnetic resonance imaging (225) 225
octreotide acetate (223) 223
neuroendocrine tumors - pathology (216) 216
somatostatin - administration & dosage (210) 210
somatostatin receptors (210) 210
secretion (209) 209
diabetes (208) 208
injections, subcutaneous (207) 207
acute disease (205) 205
peptides (204) 204
risk factors (203) 203
delayed-action preparations (201) 201
pancreatic neoplasms - pathology (201) 201
carcinoid tumor - drug therapy (199) 199
organometallic compounds - therapeutic use (199) 199
pediatrics (196) 196
research (194) 194
somatostatin - pharmacology (192) 192
young adult (189) 189
double-blind method (186) 186
drug therapy, combination (186) 186
survival (186) 186
radiotherapy (185) 185
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5957) 5957
German (112) 112
French (106) 106
Spanish (102) 102
Japanese (70) 70
Italian (46) 46
Russian (44) 44
Chinese (38) 38
Hungarian (28) 28
Polish (11) 11
Portuguese (11) 11
Danish (8) 8
Korean (6) 6
Czech (5) 5
Hebrew (5) 5
Croatian (4) 4
Dutch (4) 4
Norwegian (4) 4
Ukrainian (4) 4
Turkish (2) 2
Afrikaans (1) 1
Finnish (1) 1
Lithuanian (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Octreotide
: from basic science to clinical medicine
by Scarpignato, C
1996, Progress in basic and clinical pharmacology, ISBN 3805560559, Volume 10, xiv, 312
Octreotide acetate | Octreotide | therapeutic use
Book
Details down arrow
2. Full Text Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome
by Kulke, Matthew H and Hörsch, Dieter and Caplin, Martyn E and Anthony, Lowell B and Bergsland, Emily and Öberg, Kjell and Welin, Staffan and Warner, Richard R.P and Lombard-Bohas, Catherine and Kunz, Pamela L and Grande, Enrique and Valle, Juan W and Fleming, Douglas and Lapuerta, Pablo and Banks, Phillip and Jackson, Shanna and Zambrowicz, Brian and Sands, Arthur T and Pavel, Marianne and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Endokrin tumörbiologi and Uppsala universitet and Institutionen för medicinska vetenskaper
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 1, pp. 14 - 23
Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with... 
POPULATION | OCTREOTIDE | DIAGNOSIS | MANAGEMENT | SEROTONIN SYNTHESIS | ONCOLOGY | DISEASE | QUALITY-OF-LIFE | NEUROENDOCRINE-TUMORS | ETIPRATE | Nausea - chemically induced | Phenylalanine - adverse effects | Phenylalanine - analogs & derivatives | gamma-Glutamyltransferase - blood | Humans | Middle Aged | Male | Malignant Carcinoid Syndrome - complications | Malignant Carcinoid Syndrome - drug therapy | Diarrhea - urine | Antineoplastic Agents, Hormonal - therapeutic use | Female | Phenylalanine - therapeutic use | Malignant Carcinoid Syndrome - urine | Somatostatin - analogs & derivatives | Double-Blind Method | Defecation - drug effects | Octreotide - therapeutic use | Pyrimidines - therapeutic use | Gastrointestinal Agents - therapeutic use | Pyrimidines - adverse effects | Peptides, Cyclic - therapeutic use | Diarrhea - etiology | Aged | Diarrhea - drug therapy | Hydroxyindoleacetic Acid - urine | Somatostatin - therapeutic use | Tryptophan Hydroxylase - antagonists & inhibitors | Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Evidence-based treatment of acute pancreatitis: A look at established paradigms
by Heinrich, Stefan and Schäfer, Markus and Rousson, Valentin and Clavien, Pierre-Alain
Annals of Surgery, ISSN 0003-4932, 02/2006, Volume 243, Issue 2, pp. 154 - 168
Background: The management of acute pancreatitis (AP) is still based on speculative and unproven paradigms in many centers, Therefore, we performed an... 
CONTROLLED CLINICAL-TRIAL | EARLY ENTERAL NUTRITION | HIGH-DOSE OCTREOTIDE | SURGERY | BILE-DUCT STONES | ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY | ACUTE BILIARY PANCREATITIS | EARLY ANTIBIOTIC-TREATMENT | ACUTE NECROTIZING PANCREATITIS | DOUBLE-BLIND | PLATELET-ACTIVATING-FACTOR | Cholecystectomy | Imipenem - therapeutic use | Pancreatitis, Acute Necrotizing - drug therapy | Acute Disease | Humans | Platelet Activating Factor - antagonists & inhibitors | Leucine - therapeutic use | Sphincterotomy, Endoscopic | Antibiotic Prophylaxis | Enteral Nutrition | Pancreatitis - drug therapy | Evidence-Based Medicine | Octreotide - therapeutic use | Pancreatitis - surgery | Aprotinin - therapeutic use | Randomized Controlled Trials as Topic | Serine Proteinase Inhibitors - therapeutic use | Anti-Bacterial Agents - therapeutic use | Gabexate - therapeutic use | Pancreatitis, Acute Necrotizing - surgery | Gastrointestinal Agents - therapeutic use | Imidazoles - therapeutic use | Leucine - analogs & derivatives | Thienamycins - therapeutic use | Index Medicus | Abridged Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide
by Kulke, Matthew H and O'Dorisio, Thomas and Phan, Alexandria and Bergsland, Emily and Law, Linda and Banks, Phillip and Freiman, Joel and Frazier, Kenny and Jackson, Jessica and Yao, James C and Kvols, Larry and Lapuerta, Pablo and Zambrowicz, Brian and Fleming, Douglas and Sands, Arthur
Endocrine-Related Cancer, ISSN 1351-0088, 10/2014, Volume 21, Issue 5, pp. 705 - 714
Serotonin produced by neuroendocrine tumors is believed to be a principal cause of the diarrhea in carcinoid syndrome. We assessed the safety and efficacy of... 
Tryptophan hydroxylase | Diarrhea | Adult | Serotonin | Neuroendocrine tumor | Carcinoid syndrome | serotonin | HEART-DISEASE | NEUROENDOCRINE TUMORS | ONCOLOGY | ENDOCRINOLOGY & METABOLISM | tryptophan hydroxylase | neuroendocrine tumor | carcinoid syndrome | adult | diarrhea | Malignant Carcinoid Syndrome - urine | Phenylalanine - adverse effects | Phenylalanine - analogs & derivatives | Humans | Middle Aged | Serotonin Antagonists - therapeutic use | Male | Treatment Outcome | Octreotide - therapeutic use | Malignant Carcinoid Syndrome - drug therapy | Diarrhea - urine | Serotonin Antagonists - adverse effects | Pyrimidines - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Gastrointestinal Agents - therapeutic use | Pyrimidines - adverse effects | Aged, 80 and over | Female | Aged | Diarrhea - drug therapy | Hydroxyindoleacetic Acid - urine | Phenylalanine - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
by Kratochwil, C and Kratochwil, C and Giesel, F.L and Giesel, F.L and Bruchertseifer, F and Bruchertseifer, F and Mier, W and Mier, W and Apostolidis, C and Apostolidis, C and Boll, R and Boll, R and Murphy, K and Murphy, K and Haberkorn, U and Haberkorn, U and Morgenstern, A and Morgenstern, A
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 2014, Volume 41, Issue 11, pp. 2106 - 2119
Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as (90)Y/(177)Lu-DOTATOC is a new therapeutic option in neuroendocrine... 
DOTATOC | Targeted alpha therapy (TAT) | 225 Ac | 213 Bi | Humans | Alpha Particles - adverse effects | Male | Tomography, X-Ray Computed | Positron-Emission Tomography | Bismuth - therapeutic use | Octreotide - pharmacokinetics | Alpha Particles - therapeutic use | Neoplasm Metastasis | Neuroendocrine Tumors - diagnostic imaging | Treatment Failure | Adult | Female | Receptors, Somatostatin - metabolism | Retrospective Studies | Molecular Targeted Therapy - methods | Neuroendocrine Tumors - pathology | Molecular Targeted Therapy - adverse effects | Radioisotopes - therapeutic use | Octreotide - analogs & derivatives | Octreotide - adverse effects | Octreotide - therapeutic use | Octreotide - pharmacology | Neuroendocrine Tumors - radiotherapy | Beta Particles - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
by Pavel, Marianne E, Prof and Hainsworth, John D, Prof and Baudin, Eric, MD and Peeters, Marc, Prof and Hörsch, Dieter, Prof and Winkler, Robert E, MD and Klimovsky, Judith, MD and Lebwohl, David, MD and Jehl, Valentine, MSc and Wolin, Edward M, MD and Öberg, Kjell, Prof and Van Cutsem, Eric, Prof and Yao, James C, Dr and RADIANT 2 Study Grp and RADIANT-2 Study Group and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper and Medicin
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9808, pp. 2005 - 2012
Summary Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown antitumour activity in patients with advanced... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | PROGNOSTIC-FACTORS | NEOPLASMS | PATHWAY | PROGRESSION-FREE SURVIVAL | AGENTS | AKT | CANCER-THERAPY | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Double-Blind Method | Carcinoid Tumor - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Octreotide - therapeutic use | Disease Progression | Carcinoid Tumor - pathology | Young Adult | Malignant Carcinoid Syndrome - drug therapy | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Drug Therapy, Combination | Delayed-Action Preparations | Everolimus | Health aspects | Rapamycin | Drug therapy, Combination | Development and progression | Care and treatment | Metastasis | Angiogenesis inhibitors | Analysis | TOR protein | Medical services | Diarrhea | Fatigue | Octreotide | Patients | Survival | Metastases | Anticancer properties | Rank tests | Stomatitis | Randomization | Cell growth | Interactive systems | Pancreas | Drug dosages | Tumors | Neuroendocrine tumors | Clinical medicine | Ovarian cancer | Index Medicus | Abridged Index Medicus | Side effects | fatigue | tumors | Reviews | survival | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
by Colao, A and Bronstein, M. D and Freda, P and Gu, F and Shen, C.-C and Gadelha, M and Fleseriu, M and van der Lely, A. J and Farrall, A. J and Hermosillo Reséndiz, K and Ruffin, M and Chen, Y and Sheppard, M and Pasireotide C2305 Study Grp and Pasireotide C2305 Study Group and on behalf of the Pasireotide C2305 Study Group
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 03/2014, Volume 99, Issue 3, pp. 791 - 799
Context: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold... 
MORTALITY | SOM230 | IGF-I | MULTICENTER | MANAGEMENT | GROWTH-HORMONE | SAFETY | SOMATOSTATIN | TOLERABILITY | ENDOCRINOLOGY & METABOLISM | HEALTHY-VOLUNTEERS | Somatostatin - analogs & derivatives | Humans | Middle Aged | Growth Hormone-Secreting Pituitary Adenoma - complications | Male | Octreotide - therapeutic use | Growth Hormone-Secreting Pituitary Adenoma - drug therapy | Acromegaly - drug therapy | Young Adult | Acromegaly - etiology | Adenoma - complications | Antineoplastic Agents, Hormonal - therapeutic use | Adenoma - drug therapy | Adolescent | Aged, 80 and over | Adult | Female | Aged | Somatostatin - therapeutic use | Therapeutic Equivalency | Index Medicus | Abridged Index Medicus | Endocrine Care
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study
by Wild, Damian and Fani, Melpomeni and Fischer, Richard and Pozzo, Luigi Del and Kaul, Felix and Krebs, Simone and Rivier, Jean E. F and Reubi, Jean Claude and Maecke, Helmut R and Weber, Wolfgang A
Journal of Nuclear Medicine, ISSN 0161-5505, 08/2014, Volume 55, Issue 8, pp. 1248 - 1252
Preclinical and clinical studies have indicated that somatostatin receptor (sst)-expressing tumors demonstrate higher uptake of radiolabeled sst antagonists... 
Somatostatin receptor targeting | Antagonists | Neuroendocrine tumors | antagonists | somatostatin receptor targeting | TUMORS | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | neuroendocrine tumors | Humans | Tomography, Emission-Computed, Single-Photon | Male | Tomography, X-Ray Computed | Octreotide - pharmacokinetics | Oligopeptides - adverse effects | Feasibility Studies | Oligopeptides - therapeutic use | Receptors, Somatostatin - agonists | Neuroendocrine Tumors - diagnostic imaging | Organometallic Compounds - therapeutic use | Adult | Female | Radiometry | Receptors, Somatostatin - antagonists & inhibitors | Lutetium - therapeutic use | Amino Acid Sequence | Radioisotopes - therapeutic use | Octreotide - analogs & derivatives | Organometallic Compounds - adverse effects | Oligopeptides - pharmacokinetics | Octreotide - adverse effects | Organometallic Compounds - pharmacokinetics | Treatment Outcome | Octreotide - therapeutic use | Octreotide - pharmacology | Neuroendocrine Tumors - radiotherapy | Pilot Projects | Aged | Oligopeptides - pharmacology | Organometallic Compounds - pharmacology | Bone marrow | Nuclear medicine | Peptides | Medical treatment | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The clinical characteristics of headache in patients with pituitary tumours
by Levy, M.J and Matharu, M.S and Meeran, K and Powell, M and Goadsby, P.J
Brain, ISSN 0006-8950, 2005, Volume 128, Issue 8, pp. 1921 - 1930
The clinical characteristics of 84 patients with pituitary tumour who had troublesome headache were investigated. The patients presented with chronic (46%) and... 
Headache | Pituitary tumour | Cluster headache | Migraine | OCTREOTIDE | ATTACKS | CLUSTER-LIKE HEADACHE | migraine | NEUROSCIENCES | CLINICAL NEUROLOGY | SOMATOSTATIN | cluster headache | DOUBLE-BLIND | DOPAMINE | ADENOMA | pituitary tumour | headache | HYPOTHALAMIC ACTIVATION | PROLACTINOMAS | Headache - etiology | Humans | Dopamine Agonists - therapeutic use | Male | Bromocriptine - therapeutic use | Pituitary Neoplasms - complications | Adenoma - complications | Pituitary Neoplasms - therapy | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Migraine Disorders - physiopathology | Adult | Female | Disability Evaluation | Severity of Illness Index | Somatostatin - analogs & derivatives | Headache - physiopathology | Octreotide - therapeutic use | Pituitary Neoplasms - physiopathology | Ergolines - therapeutic use | Adenoma - physiopathology | Migraine Disorders - etiology | Peptides, Cyclic - therapeutic use | Headache - therapy | Somatostatin - therapeutic use | Aminoquinolines - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
by Garkavij, Michael and Nickel, Mattias and Sjögreen-Gleisner, Katarina and Ljungberg, Michael and Ohlsson, Tomas and Wingårdh, Karin and Strand, Sven-Erik and Tennvall, Jan
Cancer, ISSN 0008-543X, 02/2010, Volume 116, Issue 4, pp. 1084 - 1092
(177)Lu-(DOTA0,Tyr3) octreotate is a new treatment modality for disseminated neuroendocrine tumors. According to a consensus protocol, the calculated maximally... 
Octreotate | Fractionation | Imaging | Radionuclide therapy | Carcinoid | Dosimetry | Lu-177 | SPECT | Neuroendocrine tumors | Neuroendocrine Tumors - pathology | Radiotherapy Dosage | Neuroendocrine Tumors - radiotherapy | Neoplasm Metastasis | Octreotide - analogs & derivatives | Humans | Organometallic Compounds - therapeutic use | Lutetium - therapeutic use | Radiometry - methods | Octreotide - therapeutic use | Forecasting | Radiopharmaceuticals - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
by Bodei, Lisa and Kidd, Mark and Paganelli, Giovanni and Grana, Chiara M and Drozdov, Ignat and Cremonesi, Marta and Lepensky, Christopher and Kwekkeboom, Dik J and Baum, Richard P and Krenning, Eric P and Modlin, Irvin M
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 1/2015, Volume 42, Issue 1, pp. 5 - 19
Peptide receptor radionuclide therapy (PRRT) with 90Y and 177Lu provides objective responses in neuroendocrine tumours, and is well tolerated with moderate... 
PRRT | Medicine & Public Health | Orthopedics | Oncology | Bone marrow toxicity | Nuclear Medicine | Imaging / Radiology | Cardiology | NET | Nephrotoxicity | Decision tree analysis | SURVIVAL | RADIOBIOLOGY | OCTREOTATE | RADIOLABELED SOMATOSTATIN ANALOG | MYELOID NEOPLASMS | RENAL TOXICITY | RECEPTOR RADIONUCLIDE THERAPY | LU-177-DOTATATE | LEUKEMIA | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Humans | Middle Aged | Male | Leukemia, Myeloid, Acute - etiology | Neuroendocrine Tumors - diagnosis | Lutetium - administration & dosage | Yttrium Radioisotopes - administration & dosage | Aged, 80 and over | Adult | Female | Lutetium - therapeutic use | Octreotide - administration & dosage | Child | Yttrium Radioisotopes - therapeutic use | Lutetium - adverse effects | Yttrium Radioisotopes - adverse effects | Octreotide - adverse effects | Radiation Dosage | Octreotide - therapeutic use | Myelodysplastic Syndromes - etiology | Radiopharmaceuticals - administration & dosage | Neuroendocrine Tumors - radiotherapy | Adolescent | Aged | Radiopharmaceuticals - adverse effects | Radiopharmaceuticals - therapeutic use | Receptors, Peptide - metabolism | Hypertension | Hemoglobin | Leukemia | Clinical trials | Neurology | Peptides | Neurons | Endocrine system | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
by James C. Yao and Alexandria T. Phan and David Z. Chang and Robert A. Wolff and Kenneth Hess and Sanjay Gupta and Carmen Jacobs and Jeannette E. Mares and Andrea N. Landgraf and Asif Rashid and Funda Meric-Bernstam
Journal of Clinical Oncology, ISSN 0732-183X, 09/2008, Volume 26, Issue 26, pp. 4311 - 4318
Purpose Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to... 
RAPAMYCIN | IN-VITRO | EVALUATE | ONCOLOGY | CARCINOID-TUMORS | ENDOCRINE TUMORS | NEUROFIBROMATOSIS | SOMATOSTATINOMA | GROWTH-FACTOR | EXPRESSION | MTOR | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoid Tumor - drug therapy | Humans | Middle Aged | Carcinoma, Islet Cell - drug therapy | Male | Octreotide - therapeutic use | Pancreatic Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroendocrine Tumors - drug therapy | Adult | Female | Aged | Delayed-Action Preparations | Everolimus | Index Medicus | Gastrointestinal Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
by Ozdemir, Nuriye and Yazici, Ozan and Zengin, Nurullah and Yang, Feng and Jin, Chen and Fu, Deliang and Caplin, Martyn E and Pavel, Marianne and Ruszniewski, Philippe
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 16, pp. 1555 - 1557
To the Editor: In the Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors (CLARINET), Caplin et al. (July 17 issue) 1 report... 
MEDICINE, GENERAL & INTERNAL | PET | SCINTIGRAPHY | Pancreatic Neoplasms - drug therapy | Somatostatin - analogs & derivatives | Gastrointestinal Neoplasms - drug therapy | Humans | Neuroendocrine Tumors - drug therapy | Peptides, Cyclic - therapeutic use | Female | Male | Antineoplastic Agents - therapeutic use | Tomography | Octreotide | Scintigraphy | Somatostatin | Somatostatin receptors | Neuroendocrine tumors | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models
by Dalm, Simone U and Nonnekens, Julie and Doeswijk, Gabriela N and De Blois, Erik and Van Gent, DIk C and Konijnenberg, Mark W and De Jong, Marion
Journal of Nuclear Medicine, ISSN 0161-5505, 02/2016, Volume 57, Issue 2, pp. 260 - 265
Peptide receptor scintigraphy and peptide receptor radionuclide therapy using radiolabeled somatostatin receptor (SSTR) agonists are successfully used in the... 
PRRT | Therapy | Agonist | Somatostatin receptor | Antagonist | Radiopharmaceuticals - pharmacokinetics | Octreotide - analogs & derivatives | Humans | Intracellular Signaling Peptides and Proteins - metabolism | Octreotide - pharmacokinetics | Octreotide - therapeutic use | Peptides, Cyclic - pharmacokinetics | Coordination Complexes - therapeutic use | Tissue Distribution | Xenograft Model Antitumor Assays | Neuroendocrine Tumors - radiotherapy | Receptors, Somatostatin - agonists | Coordination Complexes - pharmacokinetics | Animals | Survival Analysis | Cell Line, Tumor | Peptides, Cyclic - therapeutic use | Radiometry | Receptors, Somatostatin - antagonists & inhibitors | Mice | Mice, Inbred BALB C | DNA Damage | Tumor Suppressor p53-Binding Protein 1 | Radiopharmaceuticals - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Assessment of nifedipine therapy in hyperinsulinemic hypoglycemia due to mutations in the abcc8 gene
by Güemes, Maria and Shah, Pratik and Silvera, Shavel and Morgan, Kate and Gilbert, Clare and Hinchey, Louise and Hussain, Khalid
Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, 03/2017, Volume 102, Issue 3, pp. 822 - 830
Context: Previous case reports have documented the effectiveness of L-type calcium channel blockers ( such as nifedipine and verapamil) for treating different... 
CONGENITAL HYPERINSULINISM | INHIBITION | SOMATOSTATIN | INSULIN-SECRETION | BETA-CELLS | ENDOCRINOLOGY & METABOLISM | CALCIUM-ANTAGONISTS | DILTIAZEM | ION CHANNELS | NESIDIOBLASTOSIS | CHILDREN | Prospective Studies | Humans | Calcium Channel Blockers - therapeutic use | Child, Preschool | Infant | Male | Treatment Outcome | Octreotide - therapeutic use | Congenital Hyperinsulinism - genetics | Diazoxide - therapeutic use | Nifedipine - therapeutic use | Gastrointestinal Agents - therapeutic use | Starch - therapeutic use | Sulfonylurea Receptors - genetics | Congenital Hyperinsulinism - drug therapy | Female | Glucagon - therapeutic use | Drug Therapy, Combination | Cohort Studies | Dihydroxyphenylalanine | Therapy | Intravenous administration | ABCC8 gene | Calcium | Glucagon | Positron emission | Case reports | Octreotide | Glucose | Hypoglycemia | Patients | Nifedipine | Infusion | Reduction | Computed tomography | Tomography | Verapamil | Mutation | Children | Dopa | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights